Skip to main content
Download PDF

Phenolic compounds apigenin, hesperidin and kaempferol reduce in vitro lipid accumulation in human adipocytes

Journal of Translational Medicine volume 15, Article number: 237 (2017) Cite this article

Abstract

Background

Adipocytes derived from human mesenchymal stem cells (MSCs) are widely used to investigate adipogenesis. Taking into account both the novelty of these MSCs and the scarcity of studies focused on the effects of phenolic compounds, the aim of the present study was to analyze the effect of apigenin, hesperidin and kaempferol on pre-adipocyte and mature adipocytes derived from this type of cells. In addition, the expression of genes involved in TG accumulation was also measured.

Methods

Pre-adipocytes were cultured from day 0 to day 8 and mature adipocytes for 48 h with the polyphenols at doses of 1, 10 and 25 µM.

Results

Apigenin did not show an anti-adipogenic action. Pre-adipocytes treated with hesperidin and kaempferol showed reduced TG content at the three experimental doses. Apigenin did not modify the expression of the main adipogenic genes (c/ebpβ, c/ebpα, pparγ and srebp1c), hesperidin inhibited genes involved in the three phases of adipogenesis (c/ebpβ, srebp1c and perilipin) and kaempferol reduced c/ebpβ. In mature adipocytes, the three polyphenols reduced TG accumulation at the dose of 25 µM, but not at lower doses. All compounds increased mRNA levels of atgl. Apigenin and hesperidin decreased fasn expression. The present study shows the anti-adipogenic effect and delipidating effects of apigenin, hesperidin and kaempferol in human adipocytes derived from hMSCs. While hesperidin blocks all the stages of adipogenesis, kaempferol only inhibits the early stage. Regarding mature adipocytes, the three compounds reduce TG accumulation by activating, at least in part, lipolysis, and in the case of hesperidin and apigenin, also by reducing lipogenesis.

Conclusions

The present study shows for the first time the anti-adipogenic effect and delipidating effect of apigenin, hesperidin and kaempferol in human adipocytes derived from MSCs for the first time.

Background

Overweight and obesity are considered a serious threat to public health, due to their high prevalence in our society and their association with co-morbidities such as type 2 diabetes, hypertension and cardiovascular diseases [1, 2].

In vitro studies performed using adipocytes derived from human mesenchymal stem cells (MSCs) represent a good method to analyze the two main processes that lead to adipose tissue increase and thus, to obesity development: hypertrophy (increased adipocyte size) and hyperplasia (increased adipocyte number) [1, 2]. MSCs are fibroblastoid multipotent adult stem cells with a high capacity for self-renewal. These cells have been isolated from several human tissues, such as bone marrow, adipose tissue, umbilical cord matrix, tendon, lung and periosteum, among others [3]. MSCs become adipoblasts, which subsequently commit to pre-adipocytes. Thereafter, upon adipogenic stimuli, pre-adipocytes undergo terminal differentiation into mature adipocytes [4]. Recently, it has been suggested that MSCs are a main source of adipocyte generation. Therefore, the biology of MSCs is studied in this work, as is the possible roles of MSCs in managing different components of metabolic syndrome [5,6,7].

In recent years, a great deal of attention has been paid to new active biomolecules that could be effective in preventing or treating obesity and its co-morbidities. Numerous studies have been carried out with phenolic compounds, which are members of a very large family of plant-derived compounds in the form of a wide variety of chemical structures [8]. Of these, resveratrol, quercetin and epigallocatechin have been shown to prevent fat accumulation in adipocytes through different mechanisms: by adipogenesis and lipogenesis inhibition as well as by lipolysis and fatty acid oxidation stimulation [9,10,11]. It must be pointed out that the majority of these studies have been performed in 3T3-L1 or mouse and rat primary adipocytes. However, studies demonstrating the effect of these phenolic compounds on human adipocytes are scarce to date [12,13,14,15,16,17,18,19]. Furthermore, important differences in adipocyte function exist among species, which complicates the extrapolation of results from murine adipocytes to human adipocytes [20]. Consequently, human MSCs provide an important alternative model system which represents a valuable instrument for experimental human fat cell investigation [21, 22].

Taking into account the novelty of these MSCs as an in vitro model for the study of obesity, and the few studies performed on human cells with phenolic compounds, the aim of the present study was to analyze the effect of three polyphenols (two flavonoids: apigenin and hesperidin; and one non-flavonoid: kaempferol). These polyphenols were previously studied in 3T3-L1 cells in our laboratory [23], in pre-adipocyte and mature adipocytes derived from this type of cells. In addition, the expression of genes involved in TG accumulation was also measured.

Methods

Cell samples

Human mesenchymal fat cells (hMSCs) were obtained from subcutaneous abdominal fat from a 59 year-old man with overweight and without type 2 diabetes mellitus, hypertension or dyslipidemia or obesity, as previously described [24], and approved by Clinical Investigation Ethics Committee of Aragon (Acta 11/2013).

Experimental design

Cells were cultured until confluence in DMEM 1 g/L glucose (Lonza, Verviers, Belgium) containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 4 mM glutamine, 1% penicillin/streptomycin. Differentiation was induced 2 days post-confluence (designated as day 0) with DMEM 4.5 g/L glucose (Lonza, Verviers, Belgium) supplemented with 10% FBS, 1 μM dexamethasone, 0.5 mM isobutylmethylxanthine, 1 μM rosiglitazone and 1.67 μM human insulin. This medium was changed every 72 h. At day 6, cells were incubated in a DMEM 4.5 g/L glucose medium (Lonza, Verviers, Belgium) containing 1 mM sodium pyruvate, 4 mM glutamine, 10% FBS, 1% penicillin/streptomycin and this medium was changed every 72 h until cells were treated. Cells were maintained at 37 °C in a humidified 5% CO2 atmosphere. Each experiment was performed three times.

Differentiating cells were grown in 6-well plates and incubated together with either 0.1% ethanol (95%) (control group) or with apigenin (Extrasynthese, Lyon, France), hesperidin (Extrasynthese, Lyon, France) or with kaempferol (Genay, Lyon, France) at 1, 10 or 25 µM (diluted in 95% ethanol). In a first experiment, on day 3 cells treated with phenolic compounds were used at 25 µM for TG content determination and RNA extraction. In a second experiment, on day 8 cells treated with phenolic compounds were used at 1, 10 or 25 µM for TG content determination and cells treated with 25 µM were used for RNA extraction and cytotoxicity determination.

Mature adipocytes grown in 6-well plates were also incubated with either 0.1% ethanol (95%) (control group) or with apigenin, hesperidin or kaempferol at 1, 10 or 25 μM (diluted in 95% ethanol) on day 12 after differentiation. After 48 h of treatment, supernatant was removed and cells were used for triacylglycerol (TG) determination and RNA extraction.

Triacylglycerol content

For TG determination, cells were washed with phosphate buffer saline (PBS) and incubated 3 times with 800 µL of hexane/isopropanol (2:1). The total volume was evaporated under nitrogen, and the pellet was resuspended in 100 μL of Triton X-100 in 1% distilled water. Afterward, TG were solubilized by a sonicator, and the content was measured using infinity triglycerides reagent (Spinreact, Girona, Spain). For protein determination, cells were lysed in 0.3 N NaOH and 0.1% SDS. Protein measurements were performed using the BCA reagent (Thermo Fischer Scientific, Rockford, USA).

Extraction and analysis of RNA and quantification by real-time PCR

RNA samples were extracted from cells treated with 25 µM of each phenolic compound by using Trizol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. The integrity of the RNA extracted from all samples was verified and quantified using a RNA 6000 Nano Assay (Thermo Scientific, Wilmington, DE, USA). RNA samples were then treated with DNase I kit (Applied Biosystems Inc., Foster City, CA, USA) to remove any contamination with genomic DNA.

One microgram of total RNA in a total reaction volume of 20 μL was reverse transcribed using the iScript cDNA Kit (Applied Biosystems Inc., Foster City, CA, USA) according to the manufacturer’s protocols. Reactions were incubated initially at 25 °C for 10 min and subsequently at 37 °C for 120 min and at 85 °C for 5 min.

Relative mRNA levels were quantified using real-time PCR with an iCycler MyiQ Real Time PCR Detection System (Bio-Rad, Hercules, CA, USA). 18S mRNA levels were similarly measured and served as the reference gene. The PCR reagent mixture consisted of 4.75 μL of each diluted cDNA. SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and of the upstream and downstream primers (300 nM). Specific primers for c/ebpβ (CCAAT/enhancer-binding protein beta), c/ebpα (CCAAT/enhancer-binding protein alpha), pparγ (peroxisome proliferator factor gamma), srebp1c (sterol regulatory element-binding protein 1c), acc (acetyl-CoA carboxylase), perilipin, scd1 (stearoyl-CoA desaturase 1), atgl (adipose triglyceride lipase), hsl (hormone sensitive lipase), fasn (fatty acid synthase) and dgat (diglyceride acyltransferase) were synthesized commercially and the sequences are shown in Table 1.

Table 1 Primer sequences for PCR amplification of each gene studied
Full size table

PCR parameters were as follows: initial 2 min at 50 °C, denaturation at 95 °C for 10 min followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C, except 64.5 °C for scd1 and 66.3 °C for dgat, for 30 s, and extension at 60 °C for 30 s. The results are expressed as fold changes of threshold cycle (Ct) value relative to controls using the 2−ΔΔCt method [25].

Cytotoxicity assay

Cell viability was assessed using the neutral red assay (TOX4 kit, Sigma-Aldrich, St. Louis, MO, USA) following manufacturer’s recommendations.

Statistical analysis

Results are expressed as mean ± SEM. Statistical analysis was performed using SPSS 24.0 (SPSS, Chicago IL, USA). Comparisons between each treatment and the controls were carried out by Student’s t test. Statistical significance was set at the P < 0.05 level.

Results

Effect of apigenin, hesperidin and kaempferol on triacylglycerol content and cell viability in hMSC-derived adipocytes during differentiation

While apigenin did not decrease TG content, hesperidin induced a decrease at both 10 and 25 µM and kaempferol at the three doses used (Fig. 1a–c). Apigenin, hesperidin or kaempferol did not produce a loss of viability of hMSCs even when exposed to the highest concentration of each compound (25 µM) (Fig. 2).

Fig. 1
figure 1

Triacylglycerol content in maturing pre-adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol 1 µM (a), 10 µM (b) or 25 µM (c) or not (control cells) for 8 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. Asterisks represent differences between phenolic compounds-treated cells and control cells. *P < 0.05; **P < 0.01; ***P < 0.001

Full size image
Fig. 2
figure 2

Cell viability in maturing pre-adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol at 25 µM, or not (control cells) for 8 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test

Full size image

Effect of apigenin, hesperidin and kaempferol in hMSC-derived adipocytes during differentiation

On day 3, the expression of c/ebpβ and pparγ was measured in cells treated with the three phenolic compounds at 25 µM. Apigenin did not modify the expression of these genes. By contrast, hesperidin-treated cells showed lower mRNA levels of both genes. In the case of kaempferol, cells showed a significantly reduction in pparγ gene expression and a trend towards lower values in the case of c/ebpβ (P = 0.06) (Fig. 3).

Fig. 3
figure 3

c/ebpβ (a) and pparγ (b) gene expression in maturing pre-adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol at 25 µM or not (control cells) for 3 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. *P < 0.05; **P < 0.01

Full size image

On day 8, apigenin did not modify c/ebpβ gene expression, while hesperidin and kaempferol-treated cells showed lower mRNA levels than the control cells (Fig. 4). Furthermore, gene expression of transcription factors involved in the intermediate stage of adipogenesis, c/ebpα, pparγ and srebp1c, is presented in Fig. 5. Only hesperidin significantly reduced srebp1c mRNA levels. Regarding the late stage of adipogenesis, acc, perilipin and scd1 gene expression was determined. Apigenin reduced acc and perilipin gene expression. In turn, hesperidin induced a reduction in perilipin mRNA levels (Fig. 6).

Fig. 4
figure 4

c/ebpβ gene expression in maturing pre-adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol at 25 µM or not (control cells) for 8 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. *P < 0.05

Full size image
Fig. 5
figure 5

c/ebpα (a), pparγ (b) and srebp1c (c) gene expression in maturing pre-adipocytes derived from human mesenchymal stem cells treated with hesperidin or kaempferol at 25 µM or not (control cells) for 8 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. *P < 0.05

Full size image
Fig. 6
figure 6

acc (a), perilipin (b) and scd1 (c) gene expression in maturing pre-adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol at 25 µM or not (control cells) for 8 days. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. *P < 0.05; **P < 0.01

Full size image

Effect of apigenin, hesperidin and kaempferol on triacylglycerol content in mature adipocytes derived from hMSCs

The lowest doses, 1 and 10 µM of apigenin, hesperidin or kaempferol did not reduce TG content in mature adipocytes (Fig. 7a and b). However, 25 µM of the three phenolic compounds led to a significant diminution of TG (Fig. 7c).

Fig. 7
figure 7

Triacylglycerol content in mature adipocytes derived from human mesenchymal stem cells treated with apigenin, hesperidin or kaempferol 1 µM (a), 10 µM (b) or 25 µM (c) or not (control cells) for 48 h. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. Asterisks represent differences between phenolic compounds-treated cells and control cells. *P < 0.05; **P < 0.01; ***P < 0.001

Full size image

Effect of apigenin, hesperidin and kaempferol on gene expression of mature adipocytes derived from hMSCs

Gene expression in mature adipocytes was measured at 25 µM. The three compounds increased atgl mRNA levels (Fig. 8a). In addition, apigenin and hesperidin decreased gene expression of fasn (Fig. 8e). No changes were observed in the expression of hsl, acc, dgat2 and scd1 (Fig. 8b–d, f).

Fig. 8
figure 8

Atgl (a), hsl (b), acc (c), fasn (d), dgat (e) and scd1 (f) gene expression in mature adipocytes derived from hMSCs17 stem cells treated with hesperidin or kaempferol at 25 µM or not. Values are mean ± SEM. Comparisons between each treatment and the control were analyzed by Student’s t test. *P < 0.05; **P < 0.01

Full size image

Discussion

In recent years, a large number of scientific studies have focused on phenolic compounds as potential new tools for obesity management. In this context, our group previously analyzed the effect of fifteen phenolic compounds, belonging to different chemical groups, on 3T3-L1 pre-adipocytes, in order to know the potential relationship between the efficacy on adipogenesis inhibition and the chemical structure [23].

The present work aimed to study the responses of human pre-adipocytes and adipocytes obtained from stem cells to three polyphenols: (a) apigenin, a natural flavonoid widely distributed in plant foods such as chamomile tea, grapefruit, onions, oranges and some spices like parsley, (b) hesperidin, a flavanone glycoside abundant in citrus fruits and (c) kaempferol, a natural flavonol originally isolated from tea, broccoli and other plant sources, and to compare them with those obtained previously in murine adipocytes under the same experimental conditions. We selected these three compounds because they showed greater effectiveness in our previous study carried out in 3T3-L1 [18] and because their mechanisms of action have been little studied. We carried out the experiment in a range from a physiological dose of 1 μM [26,27,28,29,30,31,32] to a high dose of 25 μM.

Apigenin did not show an anti-adipogenic action. By contrast, pre-adipocytes treated with hesperidin and kaempferol showed reduced TG content at the end of the maturation process, suggesting that these compounds induced a reduction in adipogenesis. These results are different from those obtained in our laboratory in 3T3-L1 pre-adipocytes [23]. In these cells, apigenin and kaempferol were anti-adipogenic at 10 and 25 μM, and hesperidin was effective at the three experimental doses. These results suggest that kaempferol, and mainly hesperidin, could be useful to prevent obesity in those stages of life where adipogenesis, significantly contributes to obesity development, such as childhood, adolescence and adults with severe levels of obesity. By comparing these results with those previously observed in 3T3-L1 pre-adipocytes, we can state that the latter seem to be more responsive to apigenin and hesperidin than pre-adipocyte derived from human stem cells, but not to kaempferol. This confirms the existence of important interspecies differences in adipocyte function and thus the difficulty in extrapolating results from murine adipocytes to human adipocytes.

In order to discard a potential involvement of cytotoxic effects in adipogenesis reduction, we measured cell viability when cells were incubated with the highest dose (25 μM). The study showed that the molecules did not decrease cell viability. These results are in good accordance with Morikawa et al. [33] who reported no cytotoxic effect for hesperidin at 500 μM in adipocytes derived from human bone marrow stromal cells. Other authors have performed experiments treating hMSCs at different doses, not using isolated phenolic compounds but plant extracts containing kaempferol, hesperidin and apigenin among other phenolic compounds [34, 35]. The only toxic effect was observed at the highest doses used (above 0.5 mg/mL). The authors concluded that this effect might be due to synergism between compounds present in the plant extract.

One of the objectives of the present study was to elucidate the mechanism by which apigenin, hesperidin and kaempferol reduced adipogenesis, and for that purpose the expression of genes involved in this pathway was analyzed. Three phases can be distinguished in adipogenesis: early, intermediate and late [36]. During clonal expansion, there is an induction of the early phase transcription factor, c/ebpβ, which leads to transactivation of the transcription factors of the intermediate stage pparγ, c/ebpα and srebp1c [36]. During the late phase of differentiation, adipocytes markedly increase de novo lipogenesis and acquire sensitivity to insulin. The mRNA levels of enzymes involved in TG metabolism, including acc and scd1 among others, increase 10–100 fold. The transcription factors of the intermediate stage are implicated in the activation of these last genes [37].

Under our experimental conditions, apigenin did not modify the expression of the main adipogenic genes (c/ebpβ, c/ebpα, pparγ and srebp1c) [38]. This is in good accordance with the observed lack of reduction in TG content. As far as we know, there are no studies in the literature on human adipocytes derived from stem cells treated with this phenolic compound, and thus comparisons cannot be made. By contrast, in 3T3-L1 pre-adipocytes many authors analyzed the anti-adipogenic effect of this phenolic compound. Kim et al. [39], observed that 70 μM apigenin reduced cell TG content by modulating the expression of the adipogenic transcriptional factors C/EBPβ, PPARγ and C/EBPα. These results are in good accordance with that of Ono et al. [40], who observed an anti-adipogenic effect of apigenin at 10 and 50 μM, but not at 1 mM. In our laboratory we analyzed the effect of this compound on 3T3-L1 cells in the same experimental conditions, and we observed reductions in TG content when incubations were carried out with 10 and 25 μM [23]. Other authors did not observe a reduction in TG content in the same cells at a dose of 10 μM [41].

Hesperidin inhibited genes involved in the three phases of adipogenesis, c/ebpβ srebp1c, pparγ and perilipin. These results justify the reduction in TG content induced by this phenolic compound. To the best of our knowledge, there are no in vitro studies analyzing the anti-adipogenic effect of pure hesperidin in pre-adipocytes derived from hMSCs. There is a study performed with an extract of Citrus bergamia, which contains 13% hesperidin, where hMSCs treated during differentiation showed a significant reduction in TG accumulation and pparγ expression [34]. Nevertheless, the comparison with our results is difficult because the amount of hesperidin provided to the cells in that study is far lower than that used in our experiment. In addition, it contains other phenolic compounds that may also have an effect on pre-adipocytes and interact among themselves. In 3T3-L1 pre-adipocytes, Jeon et al. [42], in good accordance with our results, observed a delipidating effect in pre-adipocytes treated with 10 and 20 μM hesperidin. Moreover, in our laboratory we observed a decrease in TG content in this type of cells when they were incubated for 8 days with 1, 10 or 25 μM. The effect was mediated by a decrease in srebp1c [23].

As far as kaempferol-treated cells are concerned, despite only c/ebpβ and pparγ being significantly reduced, an anti-adipogenic effect was observed, suggesting that the inhibition of genes involved in the early and intermediate stages of adipogenesis was enough to reduce this process. In fact, a similar situation took place in a previous study from our laboratory when 3T3-L1 pre-adipocytes were incubated with resveratrol or some of its metabolites [15]. As far as we are aware, there are no studies in the literature that demonstrate the anti-adipogenic effect of this compound in adipocytes derived from hMSCs. In 3T3-L1 pre-adipocytes, doses higher than 5 μM of kaempferol exerted a significant anti-adipogenic effect [43]. Moreover, it was observed that also at 40 μM, this compound decreased TG accumulation by the down-regulation of pparγ and srebp1c [44]. In our studies performed in this type of cells, kaempferol reduced TG content at 10 and 25 μM, but not at 1 μM. The effect was mediated by a decrease in c/ebpβ and srebp1c [23].

The present study also aimed to determine the effect of the three phenolic compounds in mature adipocytes. All of them reduced TG accumulation at the dose of 25 µM after 48 h of treatment, but not at lower doses. Taking into account that 25 µM is far higher than the serum concentrations and tissue amounts found in animals treated with polyphenols, we may say that in all likelihood these phenolic compound are not useful to reduce body fat accumulation in adult humans. Unfortunately, there are no studies in the literature showing the effects of pure apigenin, hesperidin or kaempferol on mature adipocytes derived from hMSCs. As far as plant extracts containing these phenolic compounds are concerned, Lo Furno et al. [34] showed that treating hMSCs cells with 10 or 100 µg/mL of C. bergamia extract during 7 or 14 days reduced TG accumulation. Colitti et al. [45] demonstrated that a plant extract from Citrus aurantium, containing hesperidin, reduced lipid accumulation in primary human mature adipocytes.

When the expression of genes involved in TG metabolism of mature adipocytes was analyzed, all compounds increased mRNA levels of a very well known lipase, atgl. By contrast, hsl remained unchanged. This could be explained by the fact that hsl mediates lipolysis stimulated by catecholamines and by natriuretic peptide, whereas atgl mediates the hydrolysis of TG during basal lipolysis [46]. Moreover, apigenin and hesperidin decreased gene expression of fasn. These results as a whole suggest that while the three compounds reduced TG content in mature human adipocytes by affecting, at least in part, the lipolytic process, in the case of apigenin the decrease in the lipogenic pathway also contributed to the delipidating effect.

This is the first time that the effect of pure apigenin, hesperidin and kaempferol has been tested in mature adipocytes derived from hMSCs. However, in the study of Lo Furno et al. [34], where C. bergamia extracts were used to treat hMSCs for 14 days, the authors observed that 10 and 100 µg/mL of the plant extract increased lipase protein levels, results that are in line with those of the present study [27]. As explained previously in this manuscript, a comparison with our results is difficult because of the presence of other active phenolic compounds and the potential synergism.

Conclusions

In summary, the present study shows the anti-adipogenic and delipidating effects of apigenin, hesperidin and kaempferol in human adipocytes derived from hMSCs for the first time. While hesperidin and kaempferol reduce adipogenesis, apigenin was ineffective. Regarding mature adipocytes, the three compounds (hesperidin, kaempferol and apigenin) reduce TG accumulation by activating, at least in part, lipolysis, and in the case of hesperidin and apigenin, also by reducing lipogenesis. Nevertheless, doses higher than those found in serum and plasma of animals treated with polyphenols are needed to show the delipidating effect in mature adipocytes.

Abbreviations

acc :

acetyl-CoA carboxylase

atgl :

adipose triglyceride lipase

Ct:

threshold cycle

dgat :

diglyceride acyltransferase

c/ebpα :

CCAAT/enhancer-binding protein alpha

c/ebpβ :

CCAAT/enhancer-binding protein beta

fasn :

fatty acid synthase

FBS:

fetal bovine serum

hsl :

hormone sensitive lipase

MSC:

mesenchymal stem cells

PBS:

phosphate buffer saline

pparγ :

peroxisome proliferator factor gamma

scd1 :

stearoyl-CoA desaturase 1

srebp1c :

sterol regulatory element-binding protein 1c

TG:

triacylglycerol

References

  1. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008;54:945–55.

    Article  PubMed  Google Scholar 

  2. Tang QQ, Lane MD. Adipogenesis: from stem cell to adipocyte. Annu Rev Biochem. 2012;81:715–36.

    Article  CAS  PubMed  Google Scholar 

  3. Vaz-da-Silva M, Loureiro A, Falcao A, Nunes T, Rocha J, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46:564–70.

    Article  CAS  PubMed  Google Scholar 

  4. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7:885–96.

    Article  CAS  PubMed  Google Scholar 

  5. El-Badri N, Ghoneim MA. Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges. J Nucleic Acids. 2013;2013:194858.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Marketou ME, Parthenakis FI, Kalyva A, Pontikoglou C, Maragkoudakis S, Kontaraki JE, Zacharis EA, Chlouverakis G, Patrianakos A, Papadaki HA, Vardas PE. Increased mobilization of mesenchymal stem cells in patients with essential hypertension: the effect of left ventricular hypertrophy. J Clin Hypertens (Greenwich). 2014;16:883–8.

    Article  CAS  Google Scholar 

  7. Shen H, Wang Y, Zhang Z, Yang J, Hu S, Shen Z. Mesenchymal stem cells for cardiac regenerative therapy: optimization of cell differentiation strategy. Stem Cells Int. 2015;2015:524756.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Del Rio D, Rodriguez-Mateos A, Spencer JP, Tognolini M, Borges G, Crozier A. Dietary (poly) phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal. 2013;18:1818–92.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Eseberri I, Miranda J, Lasa A, Churruca I, Portillo MP. Doses of quercetin in the range of serum concentrations exert delipidating effects in 3T3-L1 preadipocytes by acting on different stages of adipogenesis, but not in mature adipocytes. Oxid Med Cell Longev. 2015;2015:480943.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Rayalam S, Yang J, Ambati S, Della-Fera M, Baile C. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res. 2008;22:1367–71.

    Article  CAS  PubMed  Google Scholar 

  11. Wu M, Liu D, Zeng R, Xian T, Lu Y, Zeng G, Sun Z, Huang B, Huang Q. Epigallocatechin-3-gallate inhibits adipogenesis through down-regulation of PPARγ and FAS expression mediated by PI3K-AKT signaling in 3T3-L1 cells. Eur J Pharmacol. 2017;795:134–42.

    Article  CAS  PubMed  Google Scholar 

  12. Casado-Díaz A, Anter J, Dorado G, Quesada-Gómez JM. Effects of quercetin, a natural phenolic compound, in the differentiation of human mesenchymal stem cells (MSC) into adipocytes and osteoblasts. J Nutr Biochem. 2016;32:151–62.

    Article  PubMed  Google Scholar 

  13. Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin K, Fulda S, Wabitsch M. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010;92:5–15.

    Article  CAS  PubMed  Google Scholar 

  14. Gomez-Zorita S, Tréguer K, Mercader J, Carpéné C. Resveratrol directly affects in vitro lipolysis and glucose transport in human fat cells. J Physiol Biochem. 2013;69:585–93.

    Article  CAS  PubMed  Google Scholar 

  15. Lasa A, Schweiger M, Kotzbeck P, Churruca I, Simón E, Zechner R, Portillo MP. Resveratrol regulates lipolysis via adipose triglyceride lipase. J Nutr Biochem. 2012;23:379–84.

    Article  CAS  PubMed  Google Scholar 

  16. Leiherer A, Stoemmer K, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Quercetin impacts expression of metabolism- and obesity-associated genes in SGBS adipocytes. Nutrients. 2016;8:282.

    Article  PubMed Central  Google Scholar 

  17. Les F, Deleruyelle S, Cassagnes LE, Boutin JA, Balogh B, Arbones-Mainar JM, Biron S, Marceau P, Richard D, Nepveu F, et al. Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chem Biol Interact. 2016;258:115–25.

    Article  PubMed  Google Scholar 

  18. Park H, Yang J, Ambati S, Della-Fera M, Hausman D, Rayalam S, Baile C. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food. 2008;11:773–83.

    Article  CAS  PubMed  Google Scholar 

  19. Warnke I, Jocken JW, Schoop R, Toepfer C, Goralczyk R, Schwager J. Combinations of bio-active dietary constituents affect human white adipocyte function in-vitro. Nutr Metab (Lond). 2016;13:84.

    Article  Google Scholar 

  20. Entenmann G, Hauner H. Relationship between replication and differentiation in cultured human adipocyte precursor cells. Am J Physiol. 1996;270:C1011–6.

    CAS  PubMed  Google Scholar 

  21. Janderová L, McNeil M, Murrell AN, Mynatt RL, Smith SR. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes Res. 2003;11:65–74.

    Article  PubMed  Google Scholar 

  22. Nakamura M, Toyama Y. Transplantation of neural stem cells into spinal cord after injury. Nihon Rinsho. 2003;61:463–8.

    PubMed  Google Scholar 

  23. Mosqueda-Solís A, Lasa A, Gómez-Zorita S, Eseberri I, Picó C, Portillo MP. Screening of potential anti-adipogenic effects of phenolic compounds showing different chemical structure in 3T3-L1 preadipocytes. Food Funct. 2017;8:3576–86.

    Article  PubMed  Google Scholar 

  24. Perez-Diaz S, Garcia-Rodriguez B, Gonzalez-Irazabal Y, Valero M, Lagos-Lizan J, Arbones-Mainar JM. Knockdown of PTRF ameliorates adipocyte differentiation and functionality of human mesenchymal stem cells. Am J Physiol Cell Physiol. 2017;312:C83–91.

    Article  PubMed  Google Scholar 

  25. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  26. Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr. 2007;61:472–7.

    Article  CAS  PubMed  Google Scholar 

  27. Jin MJ, Kim U, Kim IS, Kim Y, Kim DH, Han SB, Kim DH, Kwon OS, Yoo HH. Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. J Toxicol Environ Health Part A. 2010;73:1441–50.

    Article  CAS  PubMed  Google Scholar 

  28. Chang L, Ren Y, Cao L, Sun Y, Sun Q, Sheng N, Yuan L, Zhi X, Zhang L. Simultaneous determination and pharmacokinetic study of six flavonoids from Fructus Sophorae extract in rat plasma by LC-MS/MS. J Chromatogr B. 2012;904:59–64.

    Article  CAS  Google Scholar 

  29. Sun H, Dong T, Zhang A, Yang J, Yan G, Sakurai T, Wu S, Han Y, Wang X. Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional chinese medicinal formulae, and its pharmacodynamics study. Phytother Res. 2013;27:1345–51.

    Article  CAS  PubMed  Google Scholar 

  30. Zhou Z, Wang M, Guo Z, Zhang X. Pharmacokinetic evaluation of the interaction between oral kaempferol and ethanol in rats. Acta Pharm. 2016;66:563–8.

    Article  CAS  PubMed  Google Scholar 

  31. Dong X, Lan W, Yin X, Yang C, Wang W, Ni J. Simultaneous determination and pharmacokinetic study of quercetin, luteolin, and apigenin in rat plasma after oral administration of Matricaria chamomilla L. extract by HPLC-UV. Evid Based Complement Altern Med. 2017;2017:8370584.

    Google Scholar 

  32. Elhennawy MG, Lin HS. Quantification of apigenin trimethyl ether in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. J Pharm Biomed Anal. 2017;142:35–41.

    Article  CAS  PubMed  Google Scholar 

  33. Morikawa K, Nonaka M, Mochizuki H, Handa K, Hanada H, Hirota K. Naringenin and hesperetin induce growth arrest, apoptosis, and cytoplasmic fat deposit in human preadipocytes. J Agric Food Chem. 2008;56:11030–7.

    Article  CAS  PubMed  Google Scholar 

  34. Lo Furno D, Graziano AC, Avola R, Giuffrida R, Perciavalle V, Bonina F, Mannino G, Cardile V. A Citrus bergamia extract decreases adipogenesis and increases lipolysis by modulating PPAR levels in mesenchymal stem cells from human adipose tissue. PPAR Res. 2016;2016:4563815.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Yunita O, Mochammad Yuwono M, Rantam FA. In vitro cytotoxicity assay of Sauropus androgynus on human mesenchymal stem cells. J Toxicol Environ Chem. 2013;95:679–86.

    Article  CAS  Google Scholar 

  36. Ntambi J, Young-Cheul K. Adipocyte differentiation and gene expression. J Nutr. 2000;130:3122S–6S.

    CAS  PubMed  Google Scholar 

  37. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev. 1998;78:783–809.

    CAS  PubMed  Google Scholar 

  38. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev. 2000;14:1293–307.

    CAS  PubMed  Google Scholar 

  39. Kim MA, Kang K, Lee HJ, Kim M, Kim CY, Nho CW. Apigenin isolated from Daphne genkwa Siebold et Zucc. inhibits 3T3-L1 preadipocyte differentiation through a modulation of mitotic clonal expansion. Life Sci. 2014;101:64–72.

    Article  CAS  PubMed  Google Scholar 

  40. Ono M, Fujimori K. Antiadipogenic effect of dietary apigenin through activation of AMPK in 3T3-L1 cells. J Agric Food Chem. 2011;59:13346–52.

    Article  CAS  PubMed  Google Scholar 

  41. Nishina A, Ukiya M, Fukatsu M, Koketsu M, Ninomiya M, Sato D, Yamamoto J, Kobayashi-Hattori K, Okubo T, Tokuoka H, Kimura H. Effects of various 5,7-dihydroxyflavone analogs on adipogenesis in 3T3-L1 cells. Biol Pharm Bull. 2015;38:1794–800.

    Article  CAS  PubMed  Google Scholar 

  42. Jeon HJ, Seo MJ, Choi HS, Lee OH, Lee BY. Gelidium elegans, an edible red seaweed, and hesperidin inhibit lipid accumulation and production of reactive oxygen species and reactive nitrogen species in 3T3-L1 and RAW264.7 cells. Phytother Res. 2014;28:1701–9.

    Article  CAS  PubMed  Google Scholar 

  43. Fang XK, Gao J, Zhu DN. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. Life Sci. 2008;82:615–22.

    Article  CAS  PubMed  Google Scholar 

  44. Park UH, Jeong JC, Jang JS, Sung MR, Youn H, Lee SJ, Kim EJ, Um J. Negative regulation of adipogenesis by kaempferol, a component of Rhizoma Polygonati falcatum in 3T3-L1 cells. Biol Pharm Bull. 2012;35:1525–33.

    Article  CAS  PubMed  Google Scholar 

  45. Colitti M, Stefanon B. Different anti-adipogenic effects of bio-compounds on primary visceral pre-adipocytes and adipocytes. EXCLI J. 2016;15:362–77.

    PubMed  PubMed Central  Google Scholar 

  46. Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Rydén M, Arner E, Sicard A, Jenkins CM, Viguerie N, et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes. 2005;54:3190–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors’ contributions

SGZ, AL, NA, AMS carried out experiments; AFQ performed experimental design and supervised results; MPGS obtained and isolated stem cells; MPO, JMAM wrote the manuscript and coordinated experiments. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Declarations

Not applicable.

Ethics approval and consent to participate

The study was approved by Clinical Investigation Ethics Committee of Aragon (Acta 11/2013).

Funding

This study was supported by grants from the Instituto de Salud Carlos III (CIBERObn), Government of the Basque Country (IT-572-13) and University of the Basque Country (UPV/EHU) (ELDUNANOTEK UFI11/32). Saioa Gómez-Zorita is a recipient of a post-doctoral fellowship from the University of the Basque Country (UPV/EHU). Jose M. Arbones-Mainar is partially funded by the Project PI14/00508 (Instituto de Salud Carlos III) and by the Fondo Europeo de Desarrollo Regional (FEDER) funds: “Una manera de hacer Europa”.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Authors and Affiliations

  1. Nutrition and Obesity Group, Department of Nutrition and Food Science and Lucio Lascaray Research Center, University of the Basque Country (UPV/EHU), Vitoria, Spain

    Saioa Gómez-Zorita, Arrate Lasa, Naiara Abendaño, Alfredo Fernández-Quintela, Andrea Mosqueda-Solís & Maria P. Portillo

  2. Adipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Instituto Aragonés de Ciencias de la Salud (IACS), Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain

    Maria Pilar Garcia-Sobreviela & Jose M. Arbonés-Mainar

  3. CIBER Fisiopatología Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain

    Saioa Gómez-Zorita, Arrate Lasa, Alfredo Fernández-Quintela, Jose M. Arbonés-Mainar & Maria P. Portillo

Authors
  1. Saioa Gómez-Zorita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arrate Lasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naiara Abendaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alfredo Fernández-Quintela
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Mosqueda-Solís
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Pilar Garcia-Sobreviela
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jose M. Arbonés-Mainar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria P. Portillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arrate Lasa.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gómez-Zorita, S., Lasa, A., Abendaño, N. et al. Phenolic compounds apigenin, hesperidin and kaempferol reduce in vitro lipid accumulation in human adipocytes. J Transl Med 15, 237 (2017). https://doi.org/10.1186/s12967-017-1343-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12967-017-1343-0

Keywords

Journal of Translational Medicine

ISSN: 1479-5876

Contact us